EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Extracellular Vesicles in Liver Fibrosis: Pathogenic Messengers, Diagnostic Biomarkers, and Therapeutic Nanovectors

Xinyi Zhao, Junyan Zhu, Tianyi Zhang, Wenrong Xu, Hui Qian

Pharmaceutics · 11.02.2026 · 18 (2) · 230

DOI: 10.3390/pharmaceutics18020230 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 11.02.2026. Verfasst von Xinyi Zhao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Laboratory Medicine of Jiangsu Province, Department of Laboratory Medicine, School of Medicine, Jiangsu University, 301 Xuefu Road,…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 187 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Natural Science Foundation of China, Zhenjiang Key Laboratory of High Technology Research on Exosomes Foundation and Transformation Application, the Priority Academic Program Development of Jiangsu Higher Education Institutions.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liver fibrosis (LF) is the final common pathological outcome of various chronic liver diseases. Advanced LF can progress to severe complications, such as cirrhosis, liver failure, and hepatocellular carcinoma (HCC). Currently, liver transplantation remains the main clinical treatment for advanced LF, but its application is limited by donor availability and unavoidable complications. Extracellular vesicles (EVs), nanoscale particles actively released by hepatic cells, including hepatocytes, hepatic stellate cells (HSCs), and macrophages), circulate in bodily fluids carrying cell-specific cargoes (e.g., RNAs, proteins). EVs mediate intercellular communication via their specific cargo profiles and contribute to the progression in LF. Increasing evidence indicates that tracking changes in the quantity and composition of EVs in LF can aid in disease diagnosis and prognosis prediction. This review discusses the pathological role of EVs in LF development and their potential as biomarkers and therapeutic targets, and provides new perspectives for future research and treatment advances.

Schlagwörter

Stichwörter der Autor:innen

diagnosisextracellular vesiclesliver fibrosispathogenesistherapy

Autor:innen und Institutionen

  • Key Laboratory of Laboratory Medicine of Jiangsu Province, Department of Laboratory Medicine, School of Medicine, Jiangsu University, 301 Xuefu Road, Zhenjiang 212013, China.
  • Department of Clinical Laboratory, Shanghai East Hospital, School of Medicine, Tongji University, 150 Ji Mo Road, Shanghai 200120, China.

Förderung

  • the National Natural Science Foundation of China
  • Zhenjiang Key Laboratory of High Technology Research on Exosomes Foundation and Transformation Application
  • the Priority Academic Program Development of Jiangsu Higher Education Institutions

Zitieren

APA

Zhao, X., Zhu, J., Zhang, T., Xu, W., & Qian, H. (2026). Extracellular Vesicles in Liver Fibrosis: Pathogenic Messengers, Diagnostic Biomarkers, and Therapeutic Nanovectors. Pharmaceutics, 18(2), 230. https://doi.org/10.3390/pharmaceutics18020230

Vancouver

Zhao X, Zhu J, Zhang T, Xu W, Qian H. Extracellular Vesicles in Liver Fibrosis: Pathogenic Messengers, Diagnostic Biomarkers, and Therapeutic Nanovectors. Pharmaceutics. 2026;18(2):230. doi:10.3390/pharmaceutics18020230

BibTeX
@article{Zhao2026,
  author = {Zhao, Xinyi and Zhu, Junyan and Zhang, Tianyi and Xu, Wenrong and Qian, Hui},
  title = {Extracellular Vesicles in Liver Fibrosis: Pathogenic Messengers, Diagnostic Biomarkers, and Therapeutic Nanovectors},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {2},
  pages = {230},
  doi = {10.3390/pharmaceutics18020230}
}
Kostenlos starten →